Search

Displaying results 1601 - 1610 of 4207 in total
  1. Drug

    Pentaerythritol tetranitrate

    go.drugbank.com/drugs/DB06154
    ApprovedWithdrawn

    It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395]. … It is formed by reacting pentaerythritol (C5H12O4), an alcohol commonly used in paints and varnishes, with nitric acid (HNO2). The reacting solution is chilled to precipitate the PETN.

  2. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    It is characterized by neurological impairment, with manifestations like loss of consciousness and seizure. … [L39195] The approval of dasiglucagon marks the first glucagon analog approved for severe hypoglycemia treatment that does not require administration by a healthcare professional.[L39195]

  3. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … [L39509] By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against

  4. Drug

    Desmopressin

    go.drugbank.com/drugs/DB00035
    ApprovedInvestigational

    It is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458

  5. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.

  6. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.

  7. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

  8. Drug

    Liraglutide

    go.drugbank.com/drugs/DB06655
    ApprovedInvestigational

    [Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.

  9. Drug

    Hepatitis A Vaccine

    go.drugbank.com/drugs/DB10989
    ApprovedInvestigational

    against the disease caused by infection with this virus. … [A199182] Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection

  10. Drug

    Phenoxyethanol

    go.drugbank.com/drugs/DB11304
    ApprovedInvestigational

    Phenoxyethanol has been classified as an antimicrobial and preservative by Health Canada [L2623]. … It is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621].